Which has higher earnings & valuation, TRLV or BLTE?

Trulieve Cannabis has higher revenue and earnings than Belite Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.14B 1.60 N/A N/A N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is TRLV or BLTE more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Trulieve Cannabis N/A N/A N/A Belite Bio N/A -11.84% -11.62%

Does the media favor TRLV or BLTE?

In the previous week, Belite Bio had 17 more articles in the media than Trulieve Cannabis. MarketBeat recorded 19 mentions for Belite Bio and 2 mentions for Trulieve Cannabis. Belite Bio's average media sentiment score of 0.63 beat Trulieve Cannabis' score of -0.20 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 5 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, LNTH or TRLV?

Lantheus has higher revenue and earnings than Trulieve Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.27 $233.56M $4.14 24.37 Trulieve Cannabis $1.14B 1.60 N/A N/A N/A

Does the media favor LNTH or TRLV?

In the previous week, Lantheus had 9 more articles in the media than Trulieve Cannabis. MarketBeat recorded 11 mentions for Lantheus and 2 mentions for Trulieve Cannabis. Lantheus' average media sentiment score of 1.01 beat Trulieve Cannabis' score of -0.20 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, TRLV or AMRX?

Amneal Pharmaceuticals has higher revenue and earnings than Trulieve Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.14B 1.60 N/A N/A N/A Amneal Pharmaceuticals $3.02B 1.95 $72.06M $0.49 37.59

Does the media prefer TRLV or AMRX?

In the previous week, Amneal Pharmaceuticals had 13 more articles in the media than Trulieve Cannabis. MarketBeat recorded 15 mentions for Amneal Pharmaceuticals and 2 mentions for Trulieve Cannabis. Amneal Pharmaceuticals' average media sentiment score of 0.52 beat Trulieve Cannabis' score of -0.20 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, EWTX or TRLV?

Trulieve Cannabis has higher revenue and earnings than Edgewise Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Trulieve Cannabis $1.14B 1.60 N/A N/A N/A

Is EWTX or TRLV more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Trulieve Cannabis N/A N/A N/A

Does the media prefer EWTX or TRLV?

In the previous week, Edgewise Therapeutics had 14 more articles in the media than Trulieve Cannabis. MarketBeat recorded 16 mentions for Edgewise Therapeutics and 2 mentions for Trulieve Cannabis. Edgewise Therapeutics' average media sentiment score of 0.50 beat Trulieve Cannabis' score of -0.20 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, TRLV or MANE?

Trulieve Cannabis has higher revenue and earnings than Veradermics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.14B 1.60 N/A N/A N/A Veradermics N/A N/A -$70M -$1.32 N/A

Is TRLV or MANE more profitable?

Company Net Margins Return on Equity Return on Assets Trulieve Cannabis N/A N/A N/A Veradermics N/A N/A N/A

Does the media refer more to TRLV or MANE?

In the previous week, Veradermics had 5 more articles in the media than Trulieve Cannabis. MarketBeat recorded 7 mentions for Veradermics and 2 mentions for Trulieve Cannabis. Veradermics' average media sentiment score of 0.61 beat Trulieve Cannabis' score of -0.20 indicating that Veradermics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veradermics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Trulieve Cannabis (TRLV) Competitors

$9.48 -0.17 (-1.76%)

As of 03:58 PM Eastern

Compare

TRLV vs. BLTE, LNTH, AMRX, EWTX, and MANE

Should you buy Trulieve Cannabis stock or one of its competitors? Trulieve Cannabis's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Edgewise Therapeutics (EWTX), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Trulieve Cannabis compare to Belite Bio?

Trulieve Cannabis (NYSE:TRLV) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Trulieve Cannabis has higher revenue and earnings than Belite Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.14B	1.60	N/A	N/A	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

In the previous week, Belite Bio had 17 more articles in the media than Trulieve Cannabis. MarketBeat recorded 19 mentions for Belite Bio and 2 mentions for Trulieve Cannabis. Belite Bio's average media sentiment score of 0.63 beat Trulieve Cannabis' score of -0.20 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	5 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trulieve Cannabis' return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Belite Bio	N/A	-11.84%	-11.62%

Trulieve Cannabis presently has a consensus price target of $15.00, suggesting a potential upside of 58.23%. Belite Bio has a consensus price target of $205.80, suggesting a potential upside of 26.10%. Given Trulieve Cannabis' higher possible upside, analysts clearly believe Trulieve Cannabis is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

0.5% of Belite Bio shares are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Belite Bio beats Trulieve Cannabis on 7 of the 11 factors compared between the two stocks.

How does Trulieve Cannabis compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Trulieve Cannabis (NYSE:TRLV) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Lantheus has higher revenue and earnings than Trulieve Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.37
Trulieve Cannabis	$1.14B	1.60	N/A	N/A	N/A

Lantheus presently has a consensus price target of $108.11, suggesting a potential upside of 7.14%. Trulieve Cannabis has a consensus price target of $15.00, suggesting a potential upside of 58.23%. Given Trulieve Cannabis' higher probable upside, analysts plainly believe Trulieve Cannabis is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lantheus had 9 more articles in the media than Trulieve Cannabis. MarketBeat recorded 11 mentions for Lantheus and 2 mentions for Trulieve Cannabis. Lantheus' average media sentiment score of 1.01 beat Trulieve Cannabis' score of -0.20 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a net margin of 17.69% compared to Trulieve Cannabis' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Trulieve Cannabis	N/A	N/A	N/A

99.1% of Lantheus shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 3.8% of Trulieve Cannabis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Lantheus beats Trulieve Cannabis on 10 of the 12 factors compared between the two stocks.

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Trulieve Cannabis (NYSE:TRLV) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Trulieve Cannabis presently has a consensus price target of $15.00, suggesting a potential upside of 58.23%. Amneal Pharmaceuticals has a consensus price target of $17.67, suggesting a potential downside of 4.09%. Given Trulieve Cannabis' higher probable upside, equities analysts plainly believe Trulieve Cannabis is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Amneal Pharmaceuticals had 13 more articles in the media than Trulieve Cannabis. MarketBeat recorded 15 mentions for Amneal Pharmaceuticals and 2 mentions for Trulieve Cannabis. Amneal Pharmaceuticals' average media sentiment score of 0.52 beat Trulieve Cannabis' score of -0.20 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a net margin of 5.05% compared to Trulieve Cannabis' net margin of 0.00%. Trulieve Cannabis' return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has higher revenue and earnings than Trulieve Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.14B	1.60	N/A	N/A	N/A
Amneal Pharmaceuticals	$3.02B	1.95	$72.06M	$0.49	37.59

Summary

Amneal Pharmaceuticals beats Trulieve Cannabis on 11 of the 13 factors compared between the two stocks.

How does Trulieve Cannabis compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Trulieve Cannabis (NYSE:TRLV) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Trulieve Cannabis' return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Trulieve Cannabis	N/A	N/A	N/A

Edgewise Therapeutics currently has a consensus price target of $49.08, suggesting a potential upside of 11.45%. Trulieve Cannabis has a consensus price target of $15.00, suggesting a potential upside of 58.23%. Given Trulieve Cannabis' higher possible upside, analysts plainly believe Trulieve Cannabis is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Trulieve Cannabis has higher revenue and earnings than Edgewise Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Trulieve Cannabis	$1.14B	1.60	N/A	N/A	N/A

In the previous week, Edgewise Therapeutics had 14 more articles in the media than Trulieve Cannabis. MarketBeat recorded 16 mentions for Edgewise Therapeutics and 2 mentions for Trulieve Cannabis. Edgewise Therapeutics' average media sentiment score of 0.50 beat Trulieve Cannabis' score of -0.20 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Edgewise Therapeutics beats Trulieve Cannabis on 5 of the 9 factors compared between the two stocks.

How does Trulieve Cannabis compare to Veradermics?

Trulieve Cannabis (NYSE:TRLV) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Trulieve Cannabis has higher revenue and earnings than Veradermics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.14B	1.60	N/A	N/A	N/A
Veradermics	N/A	N/A	-$70M	-$1.32	N/A

In the previous week, Veradermics had 5 more articles in the media than Trulieve Cannabis. MarketBeat recorded 7 mentions for Veradermics and 2 mentions for Trulieve Cannabis. Veradermics' average media sentiment score of 0.61 beat Trulieve Cannabis' score of -0.20 indicating that Veradermics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veradermics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Veradermics	N/A	N/A	N/A

Trulieve Cannabis presently has a consensus price target of $15.00, indicating a potential upside of 58.23%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 41.98%. Given Trulieve Cannabis' higher possible upside, research analysts clearly believe Trulieve Cannabis is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Veradermics beats Trulieve Cannabis on 4 of the 6 factors compared between the two stocks.

Get Trulieve Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRLV vs. The Competition

Export

Metric	Trulieve Cannabis	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.86B	$11.83B	$7.03B	$24.35B
Dividend Yield	N/A	2.69%	2.56%	3.69%
P/E Ratio	N/A	779.61	270.85	30.51
Price / Sales	1.60	745.10	597.39	20.97
Price / Cash	N/A	15.03	28.87	20.48
Price / Book	N/A	10.40	11.09	4.92
Net Income	N/A	$2.78B	$3.45B	$1.07B
7 Day Performance	5.10%	0.15%	0.74%	0.25%
1 Month Performance	7.87%	0.04%	2.15%	2.59%
1 Year Performance	N/A	145.28%	63.00%	18.80%

Trulieve Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRLV Trulieve Cannabis	3.0376 of 5 stars	$9.48 -1.8%	$15.00 +58.2%	N/A	$1.86B	$1.14B	N/A	5,000
BLTE Belite Bio	3.9112 of 5 stars	$177.58 +6.2%	$203.00 +14.3%	+144.3%	$6.70B	N/A	N/A	10	Earnings Report Analyst Forecast
LNTH Lantheus	3.42 of 5 stars	$100.68 -0.3%	$108.11 +7.4%	+86.3%	$6.59B	$1.54B	24.32	1,193	Analyst Downgrade High Trading Volume
AMRX Amneal Pharmaceuticals	3.2324 of 5 stars	$17.10 -4.4%	$17.67 +3.3%	+92.1%	$5.70B	$3.02B	34.90	8,500	Insider Trade
EWTX Edgewise Therapeutics	2.0896 of 5 stars	$44.31 -0.6%	$49.08 +10.8%	+212.2%	$4.84B	N/A	N/A	60	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TRLV) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trulieve Cannabis (TRLV) Competitors

TRLV vs. BLTE, LNTH, AMRX, EWTX, and MANE

How does Trulieve Cannabis compare to Belite Bio?

Summary

How does Trulieve Cannabis compare to Lantheus?

Summary

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Summary

How does Trulieve Cannabis compare to Edgewise Therapeutics?

Summary

How does Trulieve Cannabis compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV vs. The Competition

Trulieve Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trulieve Cannabis (TRLV) Competitors

TRLV vs. BLTE, LNTH, AMRX, EWTX, and MANE

How does Trulieve Cannabis compare to Belite Bio?

Which has higher earnings & valuation, TRLV or BLTE?

Does the media favor TRLV or BLTE?

Is TRLV or BLTE more profitable?

Do analysts recommend TRLV or BLTE?

Do insiders & institutionals have more ownership in TRLV or BLTE?

Summary

How does Trulieve Cannabis compare to Lantheus?

Which has higher valuation and earnings, LNTH or TRLV?

Do analysts recommend LNTH or TRLV?

Does the media favor LNTH or TRLV?

Is LNTH or TRLV more profitable?

Do institutionals & insiders hold more shares of LNTH or TRLV?

Summary

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Do analysts recommend TRLV or AMRX?

Do insiders and institutionals hold more shares of TRLV or AMRX?

Does the media prefer TRLV or AMRX?

Is TRLV or AMRX more profitable?

Which has stronger valuation & earnings, TRLV or AMRX?

Summary

How does Trulieve Cannabis compare to Edgewise Therapeutics?

Is EWTX or TRLV more profitable?

Do analysts prefer EWTX or TRLV?

Which has higher earnings & valuation, EWTX or TRLV?

Does the media prefer EWTX or TRLV?

Summary

How does Trulieve Cannabis compare to Veradermics?

Which has higher valuation and earnings, TRLV or MANE?

Does the media refer more to TRLV or MANE?

Is TRLV or MANE more profitable?

Do analysts prefer TRLV or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV vs. The Competition

Trulieve Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools